X0508 4 2026-02-21 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001815308 Piekos Brian C/O KALVISTA PHARMACEUTICALS, INC. 200 CROSSING BOULEVARD FRAMINGHAM MA 01702 false true false false Chief Financial Officer 0 Common Stock 2026-02-21 4 M 0 5000 A 15529 D Common Stock 2026-02-23 4 S 0 1767 15.5668 D 13762 D Restricted Stock Unit 2026-02-21 4 M 0 5000 0 D Common Stock 5000 60000 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5253 to $15.56698 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate. /s/ Benjamin L. Palleiko, Attorney-in-Fact 2026-02-24